Screener
Odyssey Therapeutics ODTX Income Statement
| Q2 '26 | Q1 '26 | Q2 '25 | ||
|---|---|---|---|---|
| $0-100% | $0-100% | $959K— | ||
| $36.23M+19.8% | $32.32M-16.6% | $30.23M— | ||
| $10.51M-20.5% | $7.35M-7.6% | $13.22M— | ||
| $55.47M+29.4% | $39.78M-3.2% | $42.88M— | ||
| -$55.47M-32.3% | -$39.78M-1.6% | -$41.92M— | ||
| $20K+900% | $10K+400% | $2K— | ||
| $2.67M+273% | $1.58M+82.8% | $716K— | ||
| -$52.8M-28.1% | -$38.2M+0.3% | -$41.21M— | ||
| -$8K-127% | $63K-55.0% | $30K— | ||
| -$52.79M-28.0% | -$38.26M+0.5% | -$41.24M— | ||
| -$1.74+94.1% | -$6.77+82.8% | -$29.54— | ||
| -$54.43M-33.9% | -$38.61M-2.0% | -$40.65M— | ||
| -$55.47M-32.3% | -$39.78M-1.6% | -$41.92M— |
FAQ
- What is Odyssey Therapeutics's revenue?
- Odyssey Therapeutics (ODTX) generated $2.9M in revenue over the trailing twelve months.
- Is Odyssey Therapeutics profitable?
- Odyssey Therapeutics is not currently profitable: it reported a net loss of $170.7M over the trailing twelve months, a -5934.0% net margin.
- What is Odyssey Therapeutics's earnings per share?
- Odyssey Therapeutics's diluted EPS over the trailing twelve months is $-77.42.
- Where does Odyssey Therapeutics's income statement data come from?
- Every line is extracted from Odyssey Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
